Every 8-K that Lunai Bioworks Inc. (LNAI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow LNAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LNAI filings page.
Lunai Bioworks, Inc. has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), which calls for a bid price of at least $1.00 per share. Nasdaq confirmed that Lunai met the conditions set by a Nasdaq Hearings Panel in prior decision and extension letters.
The company will now be subject to a mandatory one-year monitoring period under Nasdaq Listing Rule 5815(d)(4)(B). If Lunai again falls out of compliance with the bid price rule during this period, Nasdaq staff would issue a delist determination without granting additional cure time, although Lunai could request a new hearing to stay any suspension or delisting while that process concludes.
Lunai Bioworks, Inc. is implementing a 1-for-8 reverse stock split of its common stock. Every 8 issued and outstanding shares will be combined into 1 share, reducing outstanding common stock from approximately 36,271,119 shares to approximately 4,533,890 shares, subject to fractional share adjustments.
The reverse split is expected to become effective at 12:01 a.m. Eastern Time on May 22, 2026, with split-adjusted trading on The Nasdaq Capital Market beginning that day under the existing symbol LNAI and a new CUSIP number 29350E302. The move is intended primarily to help the company regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of at least $1.00 per share.
Lunai Bioworks, Inc. reported that stockholders approved key proposals at a special meeting held on May 8, 2026. The main item was an amendment to the Certificate of Incorporation authorizing a reverse stock split of common stock at a ratio between 1-for-3 and 1-for-30, with the exact ratio to be set later by the board in its sole discretion.
Proposal 1, covering the reverse split, passed with 13,571,288 votes for, 1,153,415 against, and 61,177 abstentions. Proposal 2, allowing adjournment of the meeting if needed to gather more proxies for Proposal 1, was also approved with 13,626,029 votes for, 1,091,528 against, and 68,323 abstentions. The company notes that the reverse stock split and related actions are intended to address Nasdaq continued listing requirements, including the Bid Price Rule, and refers to risks if these efforts are not successful.
Lunai Bioworks, Inc. reports that Nasdaq staff has issued an additional determination letter stating its failure to meet the $35,000,000 market value of listed securities requirement under Nasdaq Listing Rule 5550(b)(2) after the grace period expired on April 27, 2026, which may serve as another basis for delisting.
The company previously received a Panel exception through May 1, 2026 to show compliance with the $2.5 million stockholders’ equity alternative and through June 1, 2026 for the bid price rule. To support equity compliance, Lunai completed a merger on May 1, 2026 and issued $20,000,000 in stated value of Series B Preferred Stock.
On May 8, 2026, stockholders approved a reverse stock split authorization in a range of 1-for-3 to 1-for-30, and the company plans to implement a ratio that brings its share price into compliance with the bid price requirement. The company has requested a short extension from the Nasdaq Panel and warns that failure to regain compliance could lead to delisting and a move to over-the-counter trading, with potential negative effects on liquidity and capital-raising ability.
Lunai Bioworks, Inc. completed a triangular merger to acquire Neurobridge IP Holdings, whose only assets are a multi‑jurisdictional patent portfolio for Alzheimer’s disease and neurological disorders. In exchange, Lunai issued eight shares of new Series B Convertible Preferred Stock with an aggregate Stated Value of $20,000,000 and no cash.
The Series B Preferred Stock carries a senior $20,000,000 liquidation preference and is convertible, after separate stockholder approval, into up to 13,333,333 common shares at $1.50 per share, subject to beneficial ownership limits. Lunai aims to use this transaction and the preferred equity to satisfy Nasdaq’s $2.5 million stockholders’ equity requirement while it separately pursues a reverse stock split to address minimum bid price compliance.
Lunai Bioworks, Inc. is postponing its virtual Special Meeting of Stockholders from May 4, 2026 to May 8, 2026 at 9:00 a.m. Eastern Time. The meeting will still be held online and will consider proposals described in the company’s definitive proxy statement, including a Reverse Stock Split Proposal and an Adjournment Proposal.
The delay follows advice that timing rules for broker discretionary voting under New York Stock Exchange Rule 452 would likely not be met by the original date. Moving the meeting is intended to give stockholders more time to vote, help obtain a quorum, and allow brokers to vote uninstructed shares on routine matters. The record date remains April 10, 2026, and previously submitted proxies will be used unless changed or revoked.
Lunai Bioworks, Inc. entered debt exchange agreements with three noteholders, who agreed to cancel an aggregate $828,770.14 of secured promissory note principal and interest in return for 3,909,293 common shares at an implied price of $0.21 and warrants for 1,433,621 additional shares at a $0.21 exercise price, expiring on March 24, 2036.
The company also signed a binding $20.0 million Acquisition Agreement with Clemann Group SAS for blood-brain barrier delivery technology and CNS Alzheimer’s drug assets, structured as Series B Convertible Preferred Stock with a fixed $1.50 conversion price and a 19.9% beneficial ownership limitation, with no variable pricing or resets.
Lunai Bioworks, Inc. reported that on February 27, 2026 it implemented a temporary furlough of employees in the United States and Canada to help preserve liquidity while it pursues additional financing. Furloughed employees will not work for the company or receive compensation, subject to applicable laws and contracts.
The company describes the furlough as temporary, but its length depends on securing additional capital. The Chief Executive Officer and Chief Financial Officer have voluntarily agreed to temporarily defer their salaries without changing their employment terms. Lunai Bioworks is maintaining limited operations and has begun recalling certain operational employees to support ongoing platform development, with further recalls planned as circumstances permit.
Lunai Bioworks, Inc. reports that Nasdaq has moved to delist its common stock, but the company has secured a hearing to contest this decision. Lunai requested a review after receiving an initial delisting notice, and Nasdaq’s Hearings Panel has now scheduled a hearing for March 26, 2026.
Because the hearing was granted, the planned delisting is temporarily on hold until the Panel issues a final written decision. The company cautions that there is no assurance the Panel will approve continued listing or that Lunai will meet Nasdaq’s ongoing listing standards going forward.
Lunai Bioworks, Inc. reported that Nasdaq staff has determined to delist its common stock from The Nasdaq Capital Market after the shares traded below the $1.00 minimum bid price for 30 consecutive business days from December 23, 2025 through February 5, 2026.
The company is not eligible for the usual 180-day cure period because it completed a 1-for-10 reverse stock split on September 30, 2025 under Nasdaq Listing Rule 5810(c)(3)(A)(iv). Lunai has requested a hearing before a Nasdaq Hearings Panel, which temporarily stays suspension and the planned Form 25 delisting filing, but there is no assurance the appeal will succeed.
Lunai Bioworks, Inc. entered into a private placement with an accredited investor to sell 3,133,333 common shares at $1.00 per share, together with 1,044,444 three-year warrants exercisable after 60 days, for aggregate gross proceeds of $3,133,333. The transaction relies on exemptions from registration under Section 4(a)(2) and Rule 506(b), involves no underwriting discounts or commissions, and the securities are subject to resale restrictions under Rule 144. The terms are governed by a securities purchase agreement that includes customary representations, warranties, and covenants.